| Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. | |
| | |
MedLine Citation:
|
PMID: 20592748 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in onset and progression of the condition would significantly reduce the global burden of the disease. To effectively test compounds for Alzheimer's disease and bring therapy to individuals as early as possible there is an urgent need for collaboration between academic institutions, industry and regulatory organizations for the establishment of standards and networks for the identification and qualification of biological marker candidates. Biomarkers are needed to monitor drug safety, to identify individuals who are most likely to respond to specific treatments, to stratify presymptomatic patients and to quantify the benefits of treatments. Biomarkers that achieve these characteristics should enable objective business decisions in portfolio management and facilitate regulatory approval of new therapies. |
| | |
Authors:
|
Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow |
Related Documents
:
|
11177358 - Complementary and alternative therapy for nasal conditions. 15038398 - A current review of medical therapy for benign prostatic hyperplasia. 20030478 - Key articles related to complementary and alternative medicine in cardiovascular diseas... 19209288 - Bowen's disease - a review of newer treatment options. 15990618 - Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them... 9375988 - From adaptation to maladaptation--an introduction to the spectrum of circulatory respon... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 9 ISSN: 1474-1784 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-01 Completed Date: 2010-07-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 560-74 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Johann Wolfgang Goethe-University, Heinrich-Hoffmann-Str. 10, 60528 Frankfurt/Main, Germany. harald.hampel@med.uni-frankfurt.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alzheimer Disease
/
diagnosis*,
genetics Animals Biological Markers* Clinical Trials as Topic Drug Discovery / legislation & jurisprudence*, trends* Drug Industry / trends* Endpoint Determination Humans Magnetic Resonance Imaging Molecular Biology Positron-Emission Tomography Risk Assessment |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aptamers as therapeutics.
Next Document: Time-dependent expression of Arc and zif268 after acquisition of fear conditioning.